<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6CBB8CC6-3F2B-4C27-A46C-48830AD0474C"><gtr:id>6CBB8CC6-3F2B-4C27-A46C-48830AD0474C</gtr:id><gtr:firstName>Eugene</gtr:firstName><gtr:surname>Healy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F122"><gtr:id>35BA125B-C39F-4D1A-813D-560E4846D924</gtr:id><gtr:title>Melanocortin 1 receptor (MCR1) gene alterations, melanin pigment composistion, and skin cancer susceptibility</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/122</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>870727</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Natural and Environmental Sciences</gtr:department><gtr:description>Topical delivery of therapeutic agents</gtr:description><gtr:id>B03DA60E-298C-47E7-B15A-CA9A10A0BA00</gtr:id><gtr:impact>Have patented a novel cell penetrable peptide to assist delivery of therapeutic agents into human skin. Although we have had in-depth discussions with some pharmaceutical companies, there has not been take-up of the compound to date (feedback has suggested that pharmaceutical companies would prefer a carrier that is non-covalently bound to the cargo so as to avoid new cargo-carrier compounds being labelled as new drug-entities by the FDA, etc.). The act of patenting and dealing with pharmaceutical companies at an early stage of drug development has provided me with good insight into these processes.</gtr:impact><gtr:outcomeId>783420A495B-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions by collaborators to help develop cell penetrable peptide.</gtr:partnerContribution><gtr:piContribution>Helped to develop and tested a novel cell penetrable peptide to assist delivery of therapeutic agents into human skin; have shown that this carrier can transport small peptides and antisense compounds into human skin ex-vivo. Funding for cell penetrable peptide work was as part of PhD studentship from British Skin Foundation (while supervisor was funded by MRC).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Melanin analysis</gtr:description><gtr:id>E1BEE1A4-8AA4-4636-BEE1-DC54CBB912B0</gtr:id><gtr:impact>As above, an original research paper has been published (Robinson et al, J Invest Dermatol 2010 Jul;130(7):1904-13.). In addition, this was accompanied by editorial/commentary in the same issue and a podcast by Nature publishing group (who publish the J Invest Dermatol).</gtr:impact><gtr:outcomeId>41191840EC1-1</gtr:outcomeId><gtr:partnerContribution>Collaborators have quantified type and amount of melanin in skin samples</gtr:partnerContribution><gtr:piContribution>We have collaborated with chemists in Japan who have measured melanin types and amounts in skin; an original research paper has been published (Robinson et al, J Invest Dermatol 2010 Jul;130(7):1904-13).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Topic member of NICE Public Health Advisory Committee on Sunlight exposure: benefits and risks. Although commenced some years after MRC award finished, the MRC award placed me in a position to be viewed as someone with expertise in this area. Have represented NICE and presented data to WHO Global Intersun Project. Am currently Expert Advisor to NICE.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>331EF9FA-B448-4A3C-8516-3B5C5593B95F</gtr:id><gtr:impact>NICE guideline (NG34) Sunlight exposure; risks and benefits has been published 2016. I acted as topic expert on NICE Panel, and since publication have been involved in public dissemination via the media, to the World Health Organisation Global Intersun Programme, and to the Northern Ireland Department of Health Skin Cancer Prevention Strategy.

NICE guidance will impact on public health of UK population in relation to risks and benefits of sun exposure.</gtr:impact><gtr:outcomeId>545b4fa9597173.13429720</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.nice.org.uk/guidance/ng34</gtr:url><gtr:year>2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Commentary on Nature article (see http://www.nature.com/news/redhead-pigment-boosts-skin-cancer-risk-1.11711)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C6E0A90-6BD4-48A2-AF37-A71849F2F859</gtr:id><gtr:impact>Invited by Nature News to comment on publication in journal

Commentary was taken up and exhibited on several other websites around the world.</gtr:impact><gtr:outcomeId>dm5N9QQzk9j</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nature.com/news/redhead-pigment-boosts-skin-cancer-risk-1.11711</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brief TV interview on sunscreens by BBC South</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>960EA2B7-7FDF-420A-99A3-9E6D4129DB80</gtr:id><gtr:impact>Originally asked to comment on additional protection offered by SPF 50 sunscreen over that offered by SPF 30 sunscreen. However, final message was that reducing amount of sunscreen applied by 50% caused a square route reduction in the protection offered by the sunscreen (i.e. applying half the recommended amount of SPF30 gives an actual SPF of 5).

Impact unknown, but hoped that correct application of sunscreen will help to prevent development of skin cancer, especially in fair-skinned subjects.</gtr:impact><gtr:outcomeId>LLaxzymJErp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Acted as expert witness for All Party Parliamentary Group on Skin in Westminster</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E63F8BB-5DAC-464E-A9D3-1A5FD591154C</gtr:id><gtr:impact>Acted as expert witness for the All Party Parliamentary Group on Skin enquiry into the use of sun-lamps in high-street &amp;quot;tanning salons&amp;quot; in the UK.

All Party Parliamentary Group on Skin report published at end of 2008; difficult to know exact impact as development of services for skin cancer is influenced by many factors. There is also a move towards regulating the use of sunbeds / use of tanning parlours more tightly (again difficult to know exact impact of report by APPGS on this).</gtr:impact><gtr:outcomeId>6D2BDBAC7F0</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>220755</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship (I am one of three supervisors)</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Healthcare Infection Society (HIS)</gtr:fundingOrg><gtr:fundingRef>Wellcome Trust Research Training Fellowship to Dr Veronica Kinsler; eGrants reference number 10679</gtr:fundingRef><gtr:id>CAB740A4-2A14-43CA-975F-6474B90C2EE1</gtr:id><gtr:outcomeId>5E7041D17010</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institute for Health Research Academic Clinical Fellowships (I have previously supervised 4 NIHR ACFs and am currently supervising NIHR CL)</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>85045D1C-217F-4B87-B067-DEF9DBFF3ED5</gtr:id><gtr:outcomeId>FCD928EF0FD0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200445</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship (I am one of 2 supervisors)</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>Wellcome Trust Research Training Fellowship to Dr Chester Lai; 100683/Z/12/Z</gtr:fundingRef><gtr:id>4583845E-0FB1-46BF-AD85-679EDF0AA073</gtr:id><gtr:outcomeId>npQFabT9oe3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This discovery was made as a result of work carried out during a PhD studentship funded by the British Skin Foundation for which I was the main supervisor. I developed the idea, wrote the application, and supervised the project while my salary was funded by the MRC. In the project, we showed that a novel cell penetrable peptide was able to transport a 13-mer peptide and a 15-mer antisense into skin ex-vivo. The cell penetrable peptide may have the potential to allow topical treatment of skin diseases in the future, but so far there has not been any uptake by the pharmaceutical industry (see under &amp;quot;collaborations and partnership&amp;quot;).</gtr:description><gtr:grantRef>G116/122</gtr:grantRef><gtr:id>499AFBA8-0D0C-40A2-A133-8459ECCB4EED</gtr:id><gtr:impact>An application for patenting of the cell penetrable peptide has been filed in the USA (we have been informed that, at the present time, this is the market which is of most interest to pharmaceutical companies).</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>B2D6AB2D4D3</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Cell penetrable peptide</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Topic member of NICE Public Health Advisory Committee on Sunlight exposure: benefits and risks. Although commenced some years after MRC award finished, the MRC award placed me in a position to be viewed as someone with expertise in this area..</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BAD6B1DE-912D-4E6E-9698-FC52028F2F9C</gtr:id><gtr:outcomeId>545b50ebbb4929.23590168</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Acted as expert witness for review on skin cancer by All Party Parliamentary Group on Skin</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>172F984C-E2F6-434B-AF46-1F14CD7CF056</gtr:id><gtr:outcomeId>4C737257C36</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Albino and pigmented hairless mouse strain, with 50% pigmented animals, 50% albino animals. All are functionally null at the murine melanocortin 1 receptor and 50% of each group are transgenic for the human melanocortin 1 receptor.</gtr:description><gtr:id>2AF5D37B-226A-470D-9F9F-4BBD74C31145</gtr:id><gtr:impact>This tool allowed for investigation of effects of pigmentation phenotype and melanocortin 1 receptor genotype following exposure to ultraviolet radiation while controling for the variation in genetic background that would be present in studies on human volunteers. Its use in the future can be either as is (i.e. as per the current strain) or in combination with other phenotypic / genotypic characteristics through crossing with other mouse strains.</gtr:impact><gtr:outcomeId>AFBA2EED2AE</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MC1R UV model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4E4B0685-10EA-4045-A23C-8FF307D57B59</gtr:id><gtr:title>The cutaneous biochemical redox barrier: a component of the innate immune defenses against sensitization by highly reactive environmental xenobiotics.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0de159ef94ff30ecf61e288b32d8616"><gtr:id>e0de159ef94ff30ecf61e288b32d8616</gtr:id><gtr:otherNames>Pickard C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>27F82A0FE66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFE3DC8F-CE5E-4296-A77C-391F04B0C331</gtr:id><gtr:title>Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86f084aead72e278cdebfaddc19afd68"><gtr:id>86f084aead72e278cdebfaddc19afd68</gtr:id><gtr:otherNames>Cooper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14715_15_16177130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37F3E929-E408-4112-B362-1275525EEA78</gtr:id><gtr:title>Protection against UVR involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/024e0f5c16b40a2c65948d4afbe8619f"><gtr:id>024e0f5c16b40a2c65948d4afbe8619f</gtr:id><gtr:otherNames>Robinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>AnAZedTALsQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58827DD1-EB91-402F-BE0D-6BBABB06642F</gtr:id><gtr:title>Melanocortin 1 receptor variants, pigmentation, and skin cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Photodermatology, photoimmunology &amp; photomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc62385dad73c8b0266d65250c6e1a0"><gtr:id>dcc62385dad73c8b0266d65250c6e1a0</gtr:id><gtr:otherNames>Healy E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0905-4383</gtr:issn><gtr:outcomeId>pm_14715_15_15533235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91A8C223-D0A4-4154-8F9E-8729F26651B9</gtr:id><gtr:title>Expression and glycosylation of MUC1 in epidermolysis bullosa-associated and sporadic cutaneous squamous cell carcinomas.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d1114fd2efc8d84b6dd9775f85f2c7"><gtr:id>70d1114fd2efc8d84b6dd9775f85f2c7</gtr:id><gtr:otherNames>Cooper HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>pm_14715_15_15377338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70214C6A-F066-4C8A-B16A-AEA88CE6C0FB</gtr:id><gtr:title>Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/373b5486cc56231d22c34076fc57b0f8"><gtr:id>373b5486cc56231d22c34076fc57b0f8</gtr:id><gtr:otherNames>Robinson SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_14715_15_12439754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B86BE71-1FA1-4846-ACEA-80680A566B3F</gtr:id><gtr:title>Variants of the melanocortin-1 receptor: do they matter clinically?</gtr:title><gtr:parentPublicationTitle>Experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e558bc2055198ad2dea8126ba4c84c7"><gtr:id>1e558bc2055198ad2dea8126ba4c84c7</gtr:id><gtr:otherNames>Haddadeen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0906-6705</gtr:issn><gtr:outcomeId>58c007ab3bcf91.97104221</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/122</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>